Claris Lifesciences shares up 3.5% on BSE

Shares of drug firm Claris Lifesciences today rose by over 3.5 per cent as the company has received approval by the UK health regulator, Medicines and Healthcare products Regulatory Agency (MHRA) for its newly commissioned plant in Ahmedabad.
Stock of Claris Life ended the day 3.56 per cent higher at Rs 181.60 on the BSE. In intra-day, it gained 6.33 per cent to Rs 186.45.
On the volume front, 2.25 lakh shares of the company changed hands at the BSE during the day.
"This is the first regulatory inspection and compliance approval conducted by MHRA-UK in line with the EU GMP regulations for plant 2," Claris Lifesciences said in a filing on BSE.

This approval is for products presented in glass ampoules manufactured in line 1 of plant 2, it added.
"This will help in enhancing capacities to grow in regulated markets, especially the European Union. The company's speciality injectables business saw a growth of 30 per cent in the last quarter," Claris Lifesciences said.